Here are three things to know:
1. The IMblaze370 phase 3 trial included more than 360 metastatic CRC patients for whom at least two prior chemotherapy regimens had failed.
2. The majority of participants — 90 percent — had tumors characterized by microsatellite stability; tumors with microsatellite instability have been shown to respond to immunotherapy.
3. There was no significant difference in progression-free survival between the treatments.
More articles on gastroenterology:
$5k colonoscopy? Contract dispute in Mississippi could mean patients foot the bill
Pentax Medical posts lecture series on endoscopic infection control — 6 insights
Exact Sciences, Biomerica & more — 4 GI company key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
